沙利度胺口服联合5-FU和顺铂腹腔灌注治疗恶性腹水  

Thalidomide combined with 5-FU Cisplatin in the treatment of malignant ascites

作　　者：李亚星[1] 孙根林[1] 

机构地区：[1]江苏泰州市第四人民医院肿瘤内科,江苏泰州225300

出　　处：《实用临床医药杂志》2011年第17期119-120,125,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨沙利度胺治疗恶性腹水的疗效及其可能机制。方法选择胃癌20例、直肠癌10例、卵巢癌10例,经腹水细胞学证实为恶性腹腔积液病例,对照组采用顺铂60 mg加入生理盐水250 mL,5-FU 500 mg加入生理盐水250 mL腹腔灌注,而实验组在上述腹腔灌注的基础上加用沙利多胺8 mg/(kg.d)口服每晚1次。采集腹水用ELISA法检测腹水中VEGF、MMP-9、TNF-a的浓度。结果实验组和对照组相比腹水中TNF-a、VEGF和MMP-9均有下降,P值分别<0.01、0.05和0.05。实验组和对照组相比CR、NC无差异,PR、PD有差异(P<0.05),CR+PR+NC有差异(P<0.05)。结论沙利度胺抑制TNF-a表达从而抑制VEGF和MMPs表达,抑制腹水的生成。Objective To observe effect of Thalidomide in the treatment of malignant ascites and its possible mechanism.Methods Twenty patients with gastric cancer,10 cases with rectal cancer,10 cases of ovarian cancer were confirmed with malignant ascites by ascites cytology cases.In the control group,Cisplatin 60 mg,5-FU 500 mg,together with 250 mL normal saline were perfused intraperiton.But in the experimental group,oral Salle polyamine 8 mg/（kg·d） was added one night on the basis of the intraperitoneal infusion.Ascites was collected to determine concentrations of VEGF,MMP-9,and TNF-a in ascites by ELISA.Results Compared with the control group,TNF-a,VEGF and MMP-9 in ascites of the experimental group were decreased.P values were less than 0.01,0.05 and 0.05.CR and NC had no significant difference（P0.05） in the two groups.PR differed from PD（P0.05）,CR＋PR＋NC were different（P0.05）.Conclusion Thalidomide inhibits TNF-a expression and thus inhibits the expression of VEGF and MMPs,and eventually inhibits the formation of ascites.

关 键 词：沙利度胺 5-FU 顺铂 肿瘤坏死因子-A 血管内皮细胞生长因子 基质金属蛋白酶-9 腹水 

分 类 号：R730.53[医药卫生—肿瘤]